AI Lung Imaging Shows Taladegib Reduced Fibrosis in Small Phase 2a IPF Trial

AI-powered CT analysis found taladegib improved lung volume and reduced fibrosis markers in a Phase 2a IPF trial.

An AI-driven CT scanning tool detected meaningful changes in lung structure among patients with idiopathic pulmonary fibrosis (IPF) who received the experimental drug taladegib, according to data presented at the European Respiratory Society (ERS) Congress. The analysis used Brainomix 360 e-Lung software to perform quantitative imaging on scans from Endeavor BioMedicines' Phase 2a trial, designated ENV-IPF-101, of taladegib (also called ENV-101). Findings showed significant improvements in lung volume and significant reductions in measurable markers of fibrosis across multiple structural measures. Importantly, the imaging results come from a post hoc analysis — meaning they were not the trial's pre-specified primary endpoint but were applied retrospectively to the collected scan data. IPF is a progressive, life-threatening lung disease in which scar tissue steadily replaces healthy lung tissue, with few effective treatment options currently available. The presentation positions quantitative imaging biomarkers as potentially more sensitive tools for detecting drug effects in IPF trials than traditional measures, which could have implications for how future trials in this disease are designed.

Why it matters

IPF is a fatal disease with limited treatments, and more sensitive imaging biomarkers could accelerate the development and evaluation of new therapies. These results, if supported by larger trials, could validate taladegib as a candidate worth advancing.

What's next

No information on next trial phases or regulatory steps was provided in the sources.

Key facts

• The drug evaluated is taladegib (ENV-101), developed by Endeavor BioMedicines for idiopathic pulmonary fibrosis
• CT scans were analyzed using Brainomix 360 e-Lung, an AI-powered quantitative imaging platform
• Results showed significant improvement in lung volume and significant reductions in fibrosis markers
• The imaging analysis was a post hoc analysis, not the trial's pre-specified primary endpoint
• Findings were presented at the European Respiratory Society (ERS) Congress
• The trial was a Phase 2a study, an early-stage human clinical evaluation

Bias & framing notes

Both sources originate from or closely reproduce a company press release, providing no independent verification or external expert commentary. Neither source details the trial's sample size, primary endpoints, or statistical thresholds, limiting the ability to fully assess the significance of the results. The post hoc nature of the analysis — a meaningful caveat — is mentioned only briefly.

NewsClear — neutral news & congressional tracking · Bill of the Week